vs
Side-by-side financial comparison of JBG SMITH Properties (JBGS) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
JBG SMITH Properties is the larger business by last-quarter revenue ($127.6M vs $103.7M, roughly 1.2× Twist Bioscience Corp). Twist Bioscience Corp runs the higher net margin — -29.4% vs -35.7%, a 6.3% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs -2.5%).
JBG SMITH PropertiesJBGSEarnings & Financial Report
JBG SMITH Properties is a publicly traded real estate investment trust based in Bethesda, Maryland.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
JBGS vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $127.6M | $103.7M |
| Net Profit | $-45.5M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | -47.5% | -31.7% |
| Net Margin | -35.7% | -29.4% |
| Revenue YoY | -2.5% | 16.9% |
| Net Profit YoY | 24.0% | 3.4% |
| EPS (diluted) | $-0.76 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $127.6M | $103.7M | ||
| Q3 25 | $123.9M | — | ||
| Q2 25 | $126.5M | — | ||
| Q1 25 | $120.7M | — | ||
| Q4 24 | $130.8M | — | ||
| Q3 24 | $136.0M | — | ||
| Q2 24 | $135.3M | — | ||
| Q1 24 | $145.2M | — |
| Q4 25 | $-45.5M | $-30.5M | ||
| Q3 25 | $-28.6M | — | ||
| Q2 25 | $-19.2M | — | ||
| Q1 25 | $-45.7M | — | ||
| Q4 24 | $-59.9M | — | ||
| Q3 24 | $-27.0M | — | ||
| Q2 24 | $-24.4M | — | ||
| Q1 24 | $-32.3M | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -47.5% | -31.7% | ||
| Q3 25 | -27.5% | — | ||
| Q2 25 | -18.4% | — | ||
| Q1 25 | -44.7% | — | ||
| Q4 24 | -53.6% | — | ||
| Q3 24 | -22.4% | — | ||
| Q2 24 | -24.3% | — | ||
| Q1 24 | -30.1% | — |
| Q4 25 | -35.7% | -29.4% | ||
| Q3 25 | -23.1% | — | ||
| Q2 25 | -15.2% | — | ||
| Q1 25 | -37.9% | — | ||
| Q4 24 | -45.8% | — | ||
| Q3 24 | -19.8% | — | ||
| Q2 24 | -18.0% | — | ||
| Q1 24 | -22.2% | — |
| Q4 25 | $-0.76 | $-0.50 | ||
| Q3 25 | $-0.48 | — | ||
| Q2 25 | $-0.29 | — | ||
| Q1 25 | $-0.56 | — | ||
| Q4 24 | $-0.70 | — | ||
| Q3 24 | $-0.32 | — | ||
| Q2 24 | $-0.27 | — | ||
| Q1 24 | $-0.36 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $75.3M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $456.1M |
| Total Assets | $4.4B | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $75.3M | $197.9M | ||
| Q3 25 | $64.4M | — | ||
| Q2 25 | $61.4M | — | ||
| Q1 25 | $81.3M | — | ||
| Q4 24 | $145.8M | — | ||
| Q3 24 | $137.0M | — | ||
| Q2 24 | $163.5M | — | ||
| Q1 24 | $220.5M | — |
| Q4 25 | $1.2B | $456.1M | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $2.1B | — |
| Q4 25 | $4.4B | $638.1M | ||
| Q3 25 | $4.4B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.7B | — | ||
| Q4 24 | $5.0B | — | ||
| Q3 24 | $5.2B | — | ||
| Q2 24 | $5.3B | — | ||
| Q1 24 | $5.4B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $73.3M | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $73.3M | $-24.8M | ||
| Q3 25 | $8.9M | — | ||
| Q2 25 | $18.8M | — | ||
| Q1 25 | $12.9M | — | ||
| Q4 24 | $129.4M | — | ||
| Q3 24 | $26.4M | — | ||
| Q2 24 | $23.8M | — | ||
| Q1 24 | $37.0M | — |
| Q4 25 | — | $-34.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -33.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 9.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JBGS
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
